Impaired quality of life of patients with acromegaly: Control of GH/IGF-I excess improves psychological subscale appearance

European Journal of Endocrinology

Volumn 158, Issue 3, 2008, Pages 305-310

  Matta, Maria P ^a   Couture, Elisabeth ^a   Cazals, Laurent ^b   Vezzosi, Delphine ^a   Bennet, Antoine ^a   Caron, Philippe ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGED; ARTICLE; BRAIN SURGERY; CONTROLLED STUDY; DISEASE CONTROL; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE;

ACROMEGALY; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; POSTOPERATIVE PERIOD; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 40949126005     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0697     Document Type: Article

References (29)

1. Feenstra J, de Herder WW, ten Havea MTH, van den Beld AW, Feelders RA, Janssen JA & van der Lely AJ. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005 365 1644-1646.
2. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C & Orskov H. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Journal of Clinical Endocrinology and Metabolism 2005 90 5627-5631.
3. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529.
4. Beauregard C, Truong U, Hardy J & Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clinical Endocrinology 2003 58 86-91.
5. Swearingen B, Barker FG, II, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM & Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3419-3426.
6. Woodhouse LJ, Mukherjee A, Shalet SM & Ezzat S. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocrine Reviews 2006 27 287-317.
7. Badia X, Webb SM, Prieto L & Lara N. Acromegaly quality of life questionnaire (AcroQoL). Health and Quality of Life Outcomes 2004 2 13.
8. Webb SM. Quality of life in acromegaly. Neuroendocrinology 2006 83 224-229.
9. Kauppinen-Makelin R, Sane T, Sintonen H, Markkanen H, Valimaki MJ, Loyttyniemi E, Niskanen L, Reunanen A & Stenman UH. Quality of life in treated patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2006 91 3891-3896.
10. Webb SM, Badia X & Surinach NL. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. European Journal of Endocrinology 2006 155 269-277.
11. Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM & Christ ER. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the acromegaly quality of life questionnaire (AcroQoL). Clinical Endocrinology 2005 63 103-110.
12. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM & Trainer PJ. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. Journal of Clinical Endocrinology and Metabolism 2005 90 3337-3341.
13. Paisley AN, Rowles SV, Roberts ME, Webb SM, Badia X, Prieto L, Shalet SM & Trainer PJ. Treatment of acromegaly improves quality of life, measured by AcroQol. Clinical Endocrinology 2007 67 358-362.
14. Webb SM, Colao A, Caron P, Corvalheiro M, Ertürk E, Pokrajac-Simeunovic A, Schopohl J, Tsagarakis S, Pearson IV, Badia. X, Caglio S & Vincenzi B. European prospective real-fife observational study of quality of life in patients with acromegaly. Endocrine Abstracts 2006 11 OC20.
15. Biermasz NR, Pereira AM, Smit JW, Romijn JA & Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. Journal of Clinical Endocrinology and Metabolism 2005 90 2731-2739.
16. Podgorski M, Robinson B, Weissberger A, Stiel J, Wang S & Brooks PM. Articular manifestations of acromegaly. Australian and New Zealand Journal of Medicine 1988 18 28-35.
17. Fatti LM, Scacchi M, Pincelli Al, Lavezzi E & Cavagnini F. Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly. Pituitary 2001 4 259-262.
18. Sze L, Schmid C, Bloch KE, Bernays R & Brandle M. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. European Journal of Endocrinology 2007 156 321-329.
19. Buyse B, Michiels E, Bouillon R, Bobbaers H & Demedts M. Relief of sleep apnoea after treatment of acromegaly: report of three cases and review of the literature. European Respiratory Journal 1997 10 1401-1404.
20. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J & Voutilainen E. A nationwide survey of mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 4081-4086.
21. Biermasz NR, van Thiel SW Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, Romijn JA & Roelfsema F. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. Journal of Clinical Endocrinology and Metabolism 2004 89 5369-5376.
22. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, Stevenaert A, Chanson P & Beckers A. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. European Journal of Endocrinology 2005 152 61-66.
23. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G & Cozzi R. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2006 91 85-92.
24. McMillan CV, Bradley C, Giannoulis M, Martin F & Sonksen PH. Preliminary development of a new individualised questionnaire measuring quality of life in older men with age-related hormonal decline: the A-RHDQoL. Health and Quality of Life Outcomes 2003 1 51.
25. Deijen JB, Arwert LI, Witlox J & Drent MI. Differential effect sizes of growth hormone replacement on quality of life, well-being and health status in growth hormone deficient patients: a meta-analysis. Health and Quality of Life Outcomes 2005 3 63.
26. Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A & Caron P. Long-term (up to 18 years) effects on GH/IGF-I hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clinical Endocrinology 2007 67 282-289.
27. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P. Cortesi L & Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Journal of Clinical Endocrinology and Metabolism 2006 91 1397-1403.
28. Hua SC, Yan YH & Chang TC. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. European Journal of Endocrinology 2006 155 831-837.
29. Bevan JS, Newell-Price J, Wass JA, Atkin SL, Bouloux PM, Chapman J, Davis JR, Howlett TA, Randava HS, Stewart PM & Viswanath A. Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective. Clinical Endocrinology, 2007 (Epub ahead of print).